1. Market Research
  2. > Pharmaceutical Market Trends
  3. > NPS Pharmaceuticals, Inc. (NPSP) - Financial and Strategic SWOT Analysis Review

NPS Pharmaceuticals, Inc. (NPSP) - Financial and Strategic SWOT Analysis Review

  • May 2014
  • -
  • GlobalData
  • -
  • 40 pages

Summary

Table of Contents

NPS Pharmaceuticals, Inc. (NPSP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on the development of specialty therapeutics for the treatment of rare diseases and disorders. The company’s only marketed product is Gattex (teduglutide) indicated for the treatment of intestinal failure associated with short bowel syndrome.

NPS Pharmaceuticals, Inc. Key Recent Developments

Mar 25, 2014: NPS Pharmaceuticals Expands Executive Leadership Team to Support its U.S. and International Growth and Global Orphan-Drug Leadership
Feb 18, 2014: NPS Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Financial Outlook for 2014
Jan 08, 2014: NPS Pharmaceuticals Reports Preliminary 2013 Results and 2014 Financial Outlook
Jan 06, 2014: NPS Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Dec 06, 2013: NPS Pharmaceuticals to Present at Oppenheimer Healthcare Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 24h.


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H2 2016

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, ...

Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) - Pipeline Review, H2 2016

Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC ...

Hypertriglyceridemia - Pipeline Review, H2 2016

Hypertriglyceridemia - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Hypertriglyceridemia - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hypertriglyceridemia – Pipeline Review, H2 2016, provides ...

Keloids - Pipeline Review, H2 2016

December 2016 $ 2000

Wounds - Pipeline Review, H2 2016

December 2016 $ 2000

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.